ALNY optimism on AMVUTTRA growth, reduced competition and pipeline progress
TradingView News cites strong AMVUTTRA cardiomyopathy launch-driven revenue and first-line market growth. It also points to extended tafamidis exclusivity, a failed rival trial, international expansion, and pipeline progress.
AMVUTTRA’s cardiomyopathy launch has driven strong revenue and first-line market growth, supported by robust access and favorable clinical data. Competitive risks have eased after tafamidis exclusivity was extended and a rival trial failed, while international expansion and pipeline progress in mivel…